However, the greatest clinical benefit has been seen with the triple combination therapy of elexacaftor–tezacaftor–ivacaftor, developed for patients with at least one F508del CFTR allele (representing 80% to 85% of patients with CF) [42]. Here, CFTR is linked to cystic fibrosis.